T1	p 114 182	patients with acute myeloid leukemia and myelodysplastic syndromes :
T2	p 185 205	Japanese multicenter
T3	p 394 475	patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS )
T4	p 521 531	cases with
T5	p 625 641	3 probable cases
T6	p 734 757	patients with MDS or in
T7	p 821 852	cases with probable or possible
T8	p 967 987	patients with AML or
T9	p 1177 1187	9 patients
T10	p 1253 1254	7
T11	p 1337 1374	patients with AML or MDS who received
T12	i 33 79	itraconazole capsules and fluconazole capsules
T13	i 338 351	fluconazole (
T14	i 366 382	itraconazole ( n
T15	i 493 505	chemotherapy
T16	i 574 586	itraconazole
T17	i 649 660	fluconazole
T18	i 882 894	itraconazole
T19	i 913 924	fluconazole
T20	i 1026 1027	.
T21	i 1152 1163	fluconazole
T22	i 1227 1245	itraconazole group
T23	i 1375 1387	chemotherapy
T24	i 1413 1429	itraconazole for
T25	i 1501 1514	fluconazole .
T26	o 84 110	systemic fungal infections
T27	o 541 566	systemic fungal infection
T28	o 669 683	Adverse events
T29	o 810 817	numbers
T30	o 821 826	cases
T31	o 853 863	infections
T32	o 1045 1055	neutrophil
T33	o 1122 1144	frequency of infection
T34	o 1324 1333	tolerated
T35	o 1401 1409	efficacy
T36	o 1450 1458	systemic